comparemela.com

Latest Breaking News On - Cyrus mozayeni - Page 1 : comparemela.com

Pheon Therapeutics Raises $120M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

City ofUnited kingdomCyrus mozayeniCariad chesterResearch corporation technologiesAtlas venturePheon therapeuticsUnited kingdom based antibody drug conjugatePerceptive advisorsBrandon capitalResearch corporationManaging partnerChief executive officerAntibody drug conjugate

Pheon rides wave of ADC interest with $120M financing

BioPharma

United kingdomPiper sandlerCyrus mozayeniAtlas venturePheon therapeuticsPerceptive advisors

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

/PRNewswire/ Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat.

City ofUnited kingdomUnited statesCyrus mozayeniJeff albersBertrand damourKellogg school of management at northwestern universityBrown universityUniversity of virginia school medicineAlliance management at bluebird bioAtlas ventureAcademy of wilderness medicineVedere bio incVedere bio ii incGlobal head of business developmentResearch corporation technologies

Gene therapy startup Vedere to close two years after launch

BioPharma

United kingdomUnited statesKevin bittermanCyrus mozayeniMission biocapitalAtlas ventureFoundation fighting blindnessVedere bioFoundation fightingFaze medicinesAmbys medicinesGene therapy

Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer

CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ Vedere Bio II, Inc., a company developing transformative, next-generation therapies for vision re.

United statesUnited kingdomAnna maria demetriadesCyrus mozayeniPrnewswire vedere bio ii incGlaucoma service at weill cornell medicineBascom palmer eye instituteWilmer eye instituteVedere bio ii incUniversity of oxfordPhysiological sciencesMission biocapitalUniversity of miami miller school medicineAccess consortiumRoche groupRd fund

vimarsana © 2020. All Rights Reserved.